Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.49 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6162968 | 1.00 | CA12 (0.50) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL6162958 | 1.00 | CA12 (0.50) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL15766566 | 1.00 | CA12 (0.50) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL6164843 | 1.00 | CA12 (0.50) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL6131093 | 1.00 | CA12 (0.50) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL5826286 | 0.98 | CA12 (0.48) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL15766432 | 0.91 | MGLL (0.52) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL497912 | 0.90 | CA12 (0.56) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL498626 | 0.86 | CA12 (0.52) | CA12CA1CA9CA2ZDHHC20 | |
| SCHEMBL6547338 | 0.85 | DNM1 (0.50) | CA12CA1CA9CA2ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1055712-B1 | Aqueous ink for ink jet recording | MITSUI CHEMICALS INC (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-6720421-B2 | STORAGE STABILITY: GOOD RAW-STOCK STORABILITY BEFORE RECORDING AND GOOD IMAGE STORABILITY AFTER RECORDING | FUJI PHOTO FILM CO., LTD. (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030166961-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | FUJI PHOTO FILM CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020161225-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | FUJI PHOTO FILM CO., LTD. | 2002-10-31 | — | — | US | disclosed |
| EP-1055712-A2 | Aqueous ink for ink jet recording | Mitsui Chemicals, Inc. (JP) | 2000-11-29 | — | — | EP | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-5658926-A | ANTICOAGULANTS, ANTIHISTAMINES, ANTIARRHYTHMIC, CARTIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0499266-B1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-5506239-A | Carbostyril derivative and platelets aggregation inhibitory agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5352659-A | Polypeptide; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES (JP) | 1994-10-04 | — | — | US | disclosed |
| US-5306808-A | Endothelin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0569592-A1 | CARBOSTYRIL DERIVATIVE AND PLATELET AGGLUTINATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0547317-A1 | Endothelin antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166961-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | UROD, ATIC, DDC | CA12 2090/4885CA1 123/4885CA9 640/4885 |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | CA12 2629/4885CA1 4501/4885CA9 2984/4885 |
| US-20020161225-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | UROD, ATIC, DDC | CA12 2090/4885CA1 123/4885CA9 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.